Podcasts about life sciences

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde sits down with JoJo Kalita, Vice President of Partnerships and ACTOverse at ACTO. JoJo is a tech leader with over a decade of experience across Operations, Customer Success, and now Partnerships, where she's helping shape the AI landscape through collaborations with global industry leaders, including work in life sciences and beyond. How do you build operational systems that drive efficiency without losing the human touch? What does "customer obsession" look like when your job is no longer customer-facing, but partnership-driven? And how can emotional intelligence turn mentorship into a ripple effect of real impact? JoJo shares the lessons behind her relationship-first leadership style, her approach to choosing the right partners, and how to leverage technology in ways that stay grounded in empathy, clarity, and outcomes.Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Alison US CA: Alison is the world's largest free online learning and skills-training platform, helping more than 50 million learners in 193+ countries build career-ready skills with 6,000+ free courses, certificates, and diplomas.eSign (iOS only): eSign is a clean, privacy-first document-signing app that works entirely on your device, letting you sign PDFs, DOCX files, images, and scans, edit and assemble pages, and export crisp 300 DPI PDFs in seconds, without accounts, cloud uploads, or compromising sensitive documents.Support the show

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Die Life-Science-Branche mit den grossen Pharma-Unternehmen ist der wichtigste Wirtschaftsfaktor in der Region. In der Branche macht man sich aber Sorgen um die Zukunft. Das zeigte sich gestern an der Tagung der Handelskammer beider Basel. Ausserdem: · Die Basler Kantonalbank macht Gewinn. Davon profitiert auch der Kanton.

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Adam Herbst, a partner in Sheppard's Healthcare industry team, to explore key insights from the 2026 J.P. Morgan Healthcare Conference and discuss both the pitfalls and opportunities the One Big Beautiful Bill (OBBBA) presents for the healthcare sector.   What we discuss in this episode: What does the increased use of technology in healthcare mean for the aging population? What key considerations should healthcare leaders keep in mind as they adapt to OBBBA when caring for aging populations? Practical challenges providers will encounter as they seek to deploy technology solutions to address additional OBBBA restrictions. How might OBBBA change the way health systems negotiate partnerships or structure payer contracts? What are some positive outcomes that could arise with these changes? Which anticipated changes in healthcare delivery excite you most about the future of health equity?   About Adam Herbst Adam Herbst is a nationally regarded authority at the intersection of healthcare law, policy and delivery, with nearly three decades of experience spanning government, health systems, nonprofits and the private sector. He advises on the full range of corporate and transactional healthcare matters including mergers, acquisitions, joint ventures and financings involving hospitals, long-term care facilities, managed care organizations and private equity funds. He is also widely recognized for his mastery of Medicaid law, financing and policy. His Medicaid work includes 1115 waivers, state-directed payments, managed care contracting, HCBS waiver design, PACE program expansion and long-term care reimbursement across multiple states. Adam regularly structures governance arrangements, negotiates complex management and administrative services agreements and guides providers and investors through multi-state regulatory approvals and compliance regimes. Clients value Adam's ability to combine inside knowledge of government with sophisticated deal experience and a genuine understanding of mission-driven care. Whether guiding a multi-state transaction, structuring a PACE or HCBS program, advising on Medicaid waivers or supporting aging and disability service organizations, he brings a holistic approach that integrates law, policy, operations and strategy, helping clients build sustainable, compliant growth models while advancing care for vulnerable populations. Before joining Sheppard, Adam served as Deputy Commissioner of the New York State Department of Health and as a special advisor to two governors, where he led major initiatives in Medicaid transformation, long-term care reform, and managed care modernization, and chaired New York's Master Plan for Aging. During the COVID-19 pandemic, he played a critical leadership role in the state's emergency response—coordinating with federal partners, standing up COVID-only nursing facilities, managing hospital surge capacity and supporting one of the largest vaccine distribution efforts in the country. His career has also included running a children's hospital, leading a major community health center and advising faith-based organizations and disability service agencies through periods of growth, transformation and financial stress.   About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, and pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, and other medical devices, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.  Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

In 2019, Nathan Hudson-Peacock was serving as an expedition doctor to a group hiking in the Indian Himalayas. At around 17,000 feet, a climber suddenly went from having a mild headache to a life‑threatening cerebral edema. On top of that, a storm was closing in. So, what did he do? How do expedition doctors keep people alive in the harshest places on Earth? Tune in to this week's episode to find out. In it, we chat with Nathan as well as high altitude physician Monica Piris, who has spent much of her time on Everest. We dig into the world of expedition medicine: the preparation, the danger, the breathtaking environments, and the moments that can reshape your understanding of the planet and the impact of climate change. Listen to American Medieval: https://americanmedieval.com/Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Raise Frequency Change Your Life | Science of Energy & nWellness w/Barb & Chance Pitcock | EP 171HINESIGHTS Podcast Episode 171What if the way you feel every day is connected to the frequency your body operates on?In Episode 171 of the HINESIGHTS Podcast, global mental health advocate and suicide prevention speaker Kevin Hines sits down with Barb and Chance Pitcock, founders of Frequense, a wellness company built on the belief that the human body functions as an energetic system.Every cell in the body communicates through signals, rhythm, and frequency. When that system is supported, we experience clearer thinking, stronger energy, emotional balance, and deeper wellbeing. When it becomes disrupted through stress, poor nutrition, or overwhelm, many of us feel mentally foggy, physically exhausted, and emotionally drained.Barb and Chance created Frequense to help people restore harmony between mind, body, and daily living through intentional wellness products designed to support mental clarity, energy, focus, rest, and recovery.In this powerful conversation we explore• The meaning of human frequency and why it matters for health• How stress and modern life disrupt our internal balance• The role of nutrition, minerals, mushrooms, and collagen in supporting the body• Why intentional wellness practices matter more than quick fixes• The emotional journey of building a mission driven company• How caring for our bodies and minds can change the trajectory of our livesThis episode is a conversation about science, wellness, resilience, and hope.It is about listening to your body.It is about restoring balance.It is about living at a frequency that allows you to thrive.Thank you to Barb and Chance Pitcock for sponsoring this episode of the HINESIGHTS Podcast and for the work they are doing to help people reconnect with their health and wellbeing.Learn more about Frequense and explore their wellness products here https://frequense.com

S5;E217 David interviews the founders of 2  Life Science portfolio companies that have been around for a while and have made significant progress in their GTM strategies. Both have been previously profiled in detail, Redbud Labs for E138 in Sep24 and Adovate for E184 in Aug25. Thus today's interviews are updates on the progress they've made against their GTM strategies. (recorded 2.18.26)Follow David on X at https://x.com/DGRollingSouth Connect On LinkedIn with David at https://www.linkedin.com/in/davidgrisell/ Follow Paul on X at https://x.com/PalmettoAngel Connect On LinkedIn with Paul at https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com.

A Inteligência Artificial não é mais uma promessa para o futuro; ela já é uma realidade transformadora na saúde. Mas como garantir que essa inovação avance com segurança jurídica e ética? No episódio de estreia da edição mensal do Afya News, mergulhamos no tema que dominou as discussões da comunidade médica: a nova resolução do CFM sobre o uso da IA na medicina. Gustavo Meirelles, Vice-Presidente Médico da Afya, recebe a advogada Renata Rothbard (sócia do Machado Meyer e especialista em Life Sciences) e o Dr. Guilherme Rodrigues (oftalmologista e editor de conteúdo da Afya) para um debate profundo sobre os limites e as oportunidades desta tecnologia. Neste bate-papo, você vai entender:A Resolução do CFM: Os pontos positivos e as áreas que ainda geram dúvidas operacionais e insegurança jurídica.O Médico como Protagonista: Por que a IA deve ser vista como uma ferramenta de apoio (co-piloto) e nunca como um substituto para a decisão clínica e o raciocínio médico.Impacto no Dia a Dia: A automação de fluxos administrativos, o monitoramento preditivo e a redução da burocracia para que o médico possa focar no que é essencial: o olho no olho com o paciente.Futuro e Educação: O risco do "desaprendizado" tecnológico e a importância de formar profissionais letrados em dados e ferramentas inteligentes.O futuro da medicina exige uma construção colaborativa entre tecnologia, direito e assistência. Assista agora e entenda como navegar nessa transição histórica. Gostou? Compartilhe este conteúdo e ajude a levar informações sobre o futuro da medicina a outros profissionais de saúde.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What does it look like when biology leaps off the page and into the MakerSpace? Join 7/8 Grade Science teacher Carli Rivers as she discusses one of Harley's Middle School projects: building 10-foot-tall oversized plant and animal cells.   Instead of just labeling a diagram, Carli's students took to the MakerSpace to engineer life-sized models. Working in pairs to tackle specific parts of a cell, students had to collaborate, problem-solve, and build.   In this video, Carli shares: Why the process of building is as vital as the biological facts themselves. How the MakerSpace became an extension of the science lab. The impact of scale: Why exploring a 10-foot cell creates a memory that lasts longer than a textbook chapter.

In this episode, Karishma interviews Tim, a patent litigator at Mintz, discussing his journey from a potential medical career to law, the skills gained in law school, and the intersection of biotechnology and law. Tim shares insights on his current role, the importance of scientific knowledge in patent law, and the challenges of explaining complex scientific concepts in legal contexts. He also offers advice for aspiring lawyers and reflects on the future of biotech and patent law in the LA ecosystem. Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

This week we are discussing life sciences in the UK, and its contribution to the UK economy. This follows the publication by the Government of the Life Sciences Sector Plan and an event on life sciences which the Foundation for Science and Technology held on 12th November. With us to explore all things life sciences is Dr Kath MacKay, Chief Scientific Officer of Bruntwood SciTech.

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.      For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com.       

There is a palpable mix of excitement and anxiety about the latest impending wave of Artificial Intelligence. AI tools are being developed that will fundamentally impact our jobs, our relationships, our access to knowledge and creativity, our children's lives, and our planet. But for an industry like healthcare — where fax machines and pagers are common, where people struggle to find affordable care or adequate resources, and nurses are leaving the profession due to administrative burdens and moral distress — can AI be an answer?  In this two-part feature of our AI in Play series, where we explore AI's role in transforming healthcare, host Oriana Beaudet, Vice President of Innovation at the American Nurses Association, Credentialing Center, and Foundation, talks with a nurse and a clinician helping to shape the future of AI in healthcare for one of the largest technology companies in the world.   Episode 130 features nurse Mary Varghese-Presti, Corporate VP and COO of Microsoft Health and Life Sciences, whose team built Dragon Copilot, the first commercially available ambient AI solution purpose-built for nursing workflows. We learn how Microsoft co-designed this tool directly with staff nurses, nurse managers, and nurse executives across more than 10 health systems,  and why that collaboration is essential. We'll learn about Microsoft's vision for a three-stage AI future, from co-pilots to agents to a true hybrid workforce, and what it would mean for nurses to have the ability to delegate tasks the way physicians have long been able to do. Finally, we hear the deeply personal story behind Mary's mission,  from growing up in an immigrant household surrounded by nurse "aunties," to advocating for a voiceless patient at 4 am as a young nurse at Johns Hopkins, to now leading the technology that she believes will restore humanity and dignity to the very profession that shaped her.  Episode 131 features Dominic King, former surgeon and VP of Health at Microsoft AI, where his team builds and scales consumer health tools that see more than 50 million health-related sessions a day. In this conversation, we learn about Microsoft's partnership with Harvard Medical School and how it's working to ensure that the billions of health questions people ask AI every day are met with credible, clinically sound information. We also hear how he thinks about patient safety and trust in AI, and we'll get his candid take on what AI cannot replace, why clinicians must be central to scaling these tools beyond the pilot stage, and how he believes technology is the single biggest lever for making health systems sustainable in the face of growing global demand.    For more information on the podcast bundles, visit ANA's Innovation Website at https://www.nursingworld.org/practice-policy/innovation/education.    Have questions or feedback for the SEE YOU NOW team?  Future episode ideas? Contact us at hello@seeyounowpodcast.com. 

Send a textAI is accelerating drug development. Precision medicine is going mainstream. Rare disease innovation is reshaping pipelines.So what's really happening inside life sciences consulting right now?In this panel, leaders from Guidehouse, Clarkston Consulting, ClearView Healthcare Partners, and Roland Berger join Management Consulted for a direct, no-fluff look at where the industry is headed — and who wins in it.You'll hear:Where AI is actually creating value (not just headlines)How firms turn complex science into commercial decisionsWhat separates candidates who get offers from those who don'tEach firm is hiring now. Click here to connect with each panelist and learn more about the firms.Resources:Explore open roles at Clarkston, ClearView, Guidehouse, and Roland BergerJoin Black Belt for a personalized recruitment plan, expert-led coaching, and targeted digital resources to break into life sciences consultingJoin the last-ever Strategy Sprint (March 7-14)Build consulting experience, boost your resume, and make a real impact on this 1-week consulting project (the last-ever project) MBB Undergrad Timelines Are Moving UpApplication deadlines are the earliest we've ever seen; join Black Belt for a structured, MBB-led prep plan + coaching + resume editsEmployee Survival Guide®A Podcast only for employees. Mark shares information your employer does not want you knowListen on: Apple Podcasts SpotifyConnect With Management Consulted Schedule free 15min consultation with the MC Team. Watch the video version of the podcast on YouTube! Follow us on LinkedIn, Instagram, and TikTok for the latest updates and industry insights! Join an upcoming live event - case interviews demos, expert panels, and more. Email us (team@managementconsulted.com) with questions or feedback.

Based on AHLA's annual Health Law Connections article, this special ten-part series brings together thought leaders from across the health law field to discuss the top ten issues of 2026. In the sixth episode, Mary R. Kohler, Founder & Principal, Kohler Health Law PC, speaks with Kristie C. Gurley, Partner, Covington & Burling LLP, about the targeted reform and broad shifts that U.S. drug pricing is currently undergoing. They discuss issues related to Inflation Reduction Act implementation, litigation, the Trump Administration's approach to drug pricing, pharmacy benefit managers, and 340B. From AHLA's Life Sciences Practice Group.Watch this episode: https://www.youtube.com/watch?v=dIdgAUQA7toRead AHLA's Top Ten 2026 article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/a879dda5-35f9-46fb-ad45-1b0799343d74/Health-Law-Forecast-2026Access all episodes in AHLA's Top Ten 2026 podcast series: https://www.americanhealthlaw.org/education-events/speaking-of-health-law-podcasts/top-ten-issues-in-health-law-podcast-seriesLearn more about AHLA's Life Sciences Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/life-sciencesEssential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Welcome to Season 5 of The Industry 4.0 Podcast with Grantek. This season we welcome our new host, Matt Susi. Matt is a Technical Consultant in Grantek's Consulting & Digital Solutions Group. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions.   Our guests will share tips and outcomes that will help improve your productivity. You will hear from manufacturers, leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve the Data Centers, Life Sciences and Food & Beverage industries.

Prefabrication works differently in highly regulated environments. In this episode of Prefab, Unfiltered, recorded live at Advancing Prefabrication, Todd Weyandt sits down with David O'Connell to explore how prefabrication, modular construction, and industrialized strategies perform inside life sciences, pharmaceutical manufacturing, and cleanroom construction. When time to market can mean tens of millions of dollars per day, construction strategy becomes a business-critical decision. But in regulated environments, every weld, inspection, and document must meet strict compliance standards. This conversation unpacks where prefabrication truly adds value in pharma and semiconductor projects, where full modular building approaches struggle, and why regulatory alignment is often the deciding factor. If you are involved in life sciences construction, cleanroom facilities, modular construction, or industrialized project delivery, this episode delivers a grounded and practical perspective.   You'll Learn Why full building modular often struggles in life sciences construction Where prefabrication works best in pharmaceutical and cleanroom environments How regulatory inspections shape prefab strategy Why partnering with agencies having jurisdiction is critical How time to market drives construction decisions in drug manufacturing The financial impact of schedule acceleration in regulated facilities   Meet Our Guest David O'Connell brings decades of experience across semiconductor, life sciences, and pharmaceutical construction. With a background shaped by multiple generations in construction and deep experience delivering highly technical facilities, he has worked at the intersection of prefabrication, regulatory compliance, and time-critical project delivery. His perspective bridges traditional construction methods and modern industrialized strategies, particularly in cleanroom environments and drug manufacturing facilities where documentation, inspection, and compliance are paramount.   Todd Takes Prefabrication Has to Respect Regulation. In pharmaceutical and life sciences construction, compliance is non-negotiable. Prefabrication does not remove regulatory scrutiny. It demands earlier coordination and stronger documentation. Inspectors and agencies must be brought in as partners, not treated as obstacles. Not Everything Should Be Modular. Full building modular has not consistently succeeded in highly regulated environments. Prefabrication often works best in repeatable components such as utility racks, panels, and cleanroom assemblies. Industrialized construction is not all or nothing. Strategic application matters. Time to Market Changes the Equation. In pharmaceutical manufacturing, delayed production can mean millions of dollars per day. That reality shifts the conversation from cost savings to schedule certainty and risk mitigation. Prefabrication becomes a strategic lever for accelerating capacity while maintaining compliance.   More Resources   Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn David's LinkedIn Verista's Website   Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website  

In this episode of Tiny Show and Tell Us, we talk about the crafty corvids that steal anti‑bird spikes to build chaotic, spiky nests and “Mitochondrial Eve” — the most recent common maternal ancestor of modern humans. Get ready for stories of sandwich‑stealing gulls, Deboki being held hostage by a peacock, and the Mitochondrial Eve/Y Chromosomal Adam romcom no one asked for.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. “Despite its promise, CAR T-cell therapy faces several critical challenges.” The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability. DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Leadership quality and organisational culture are emerging as nearly equal priorities to compensation when professionals choose and stay with employers, according to the Cpl Salary Guide for Ireland 2026. The findings reveal a fundamental shift in talent priorities, as employees increasingly evaluate opportunities based on values, work environment, and leadership behaviours alongside financial rewards. The key findings from this year's report are as follows: While compensation and benefits remain the top priority at 35%, leadership and culture follow closely at 24% as the most important factor when choosing an employer. When examining both first and second most important factors combined, leadership and culture reaches 54% (24% first choice, 30% second choice), narrowing the gap with compensation and benefits at 62% (35% first choice, 27% second choice). Within the leadership and culture category, employees prioritise culture, values and ethics (27%), work environment (25%), and leadership behaviours (24%). Cpl's findings reinforce that leadership quality remains a critical driver of employee attrition. Flexible Working: The Essential Benefit Flexible working arrangements have evolved from a perk to a critical component of employee packages. After remuneration (32%), flexible working ranks as the second most important compensation and benefit factor at 26%. The research shows that 70% of employees now utilise some form of flexible working, with previous studies indicating that one in four candidates would not proceed with a job opportunity lacking flexibility. The predominant flexibility model is hybrid working (over 54%), typically with a 3/2 or 2/3 home/office split. However, next-generation arrangements are emerging, with 12% working fully remote and over 7% utilising compressed work weeks. Organisations offering structured, design-led flexible working strategies gain a significant competitive advantage, particularly when recruiting for high-skilled roles where talent is scarce. Work-Life Balance Takes Centre Stage Within employee experience priorities, work-life balance dominates at 40%, followed by meaningful and stimulating work at 21%. While not yet surpassing compensation in importance, work-life balance, when considered alongside flexible working, represents a core pillar of any successful talent strategy. AI Transitions from Specialist to Mainstream Capability Cpl's analysis found that, between 2022 and 2024, AI references in job titles and descriptions increased year-on-year, peaking in 2024. However, 2025 saw a correction as organisations moved beyond experimentation toward strategic implementation. AI demand remains concentrated in IT (55% of AI-related hiring), Life Sciences (17%), and Customer Service (13%). Business Intelligence has emerged as a distinct growth category since 2023, signalling a shift toward insight-led decision-making. Regulatory roles now account for 3% of AI positions, reflecting growing governance requirements. Cpl found that AI is becoming embedded within existing roles rather than creating new specialist positions. By 2024-2025, AI-related roles comprised just 3% of all jobs, yet within those roles, under 50% of job titles still referenced AI. References to AI in job descriptions have doubled compared to job titles, indicating that employers increasingly expect baseline AI literacy as a standard competency rather than a differentiator. Limited Company Growth Signals Workforce Evolution Ireland experienced near-record limited company incorporations in 2025, with approximately 25,000 new companies registered (a 5-6% increase on 2024). This growth reflects layoffs and slower permanent hiring for experienced professionals, prompting many to establish their own businesses providing specialist services across technology, life sciences, and financial services. This trend signals a structural shift toward self-employment, fractional leadership, and contingent workforce models, offering organisa...

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Eric Newsom, partner and Transactions lead of Sheppard's national Healthcare industry team, to discuss key takeaways from the 2026 J.P. Morgan Healthcare Conference and explore what growing AI adoption, shifting reimbursement models and evolving macroeconomics mean for M&A and strategic partnerships.   What we discuss in this episode: How the conference addressed the growing focus on AI-powered healthcare platforms. The key factors driving adoption of AI technologies across the healthcare industry. How providers and payers are adjusting their M&A and joint‑venture strategies amid shifting reimbursement models and evolving macroeconomic pressures. The top three priorities for healthcare leaders when advancing AI adoption and structuring strategic partnerships. Topics not covered at the conference that Eric would have liked to learn more about.   About Eric Newsom Eric Newsom is a partner in the Corporate practice group in Sheppard's San Francisco office and serves as Transactions Lead of the firm's national Healthcare industry team. Eric's nationwide practice focuses on mergers and acquisitions, strategic joint ventures, corporate reorganizations, private equity and venture capital transactions, and corporate governance and compliance matters. Eric has represented buyers, sellers, investors, and intermediaries in numerous business combinations, buyouts, and investment transactions, with particular emphasis on the healthcare industry. In his healthcare and health technology practice, Eric advises on mergers, acquisitions, affiliations, comprehensive corporate reorganizations, multi-channel joint ventures, and private equity investment and disposition transactions. His experience spans for-profit, nonprofit, and government-owned hospital and provider systems; academic medical centers; health plans; physician groups; ambulatory and specialty service providers; and startup and growth-stage companies in the healthcare information technology sector.   About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, and pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, and other medical devices, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.    Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Contact Info Eric Newsom Michael Orlando    Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

The decision to bootstrap a business or raise venture capital is not just financial. It is physics. You are choosing which system to operate within, which rules will govern your company, and whose incentives will shape your options at every inflection point. Rob Taylor has lived both realities. He spent years building venture-backed companies, raising millions in institutional capital. His brother Chris bootstrapped a company for 20 years and owned nearly 100% at exit. They sold their companies the same year and ended up in roughly the same place financially. The question is what do you optimize for, and the nature of that question is changing daily in the age of AI. Recorded live at Red Fridge Society.The Agenda0:00 Intro + Defining Bootstrap vs. VC 7:23 Is Your Business VC-Backable 11:54 The Ecosystem You Gain with Institutional Capital 15:03 The Ownership Curve 20:36 Control and Governance 26:24 Disruption in the AI Era 32:41 How Fund Size Shapes Investment Behavior 37:43 The Bootstrap-VC Overlap 40:54 Choosing Your Partner 45:14 The Incremental Approach to RaisingGuest LinksRob Taylor: LinkedIn, Silverton PartnersRed Fridge Society -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

AI-first is table stakes; instead, outcomes-first delivery in collaboration with a partner ecosystem unlocks growth, access, and resilience. Key discussion points include:AI-first is no longer differentiating, but outcomes are. Most providers claim AI-first, but the real shift is to outcomes-first delivery tied to better health, better experience, lower cost, and equity. The old delivery playbook won't survive the revenue headwind and patent cliff era. Life science enterprises need a new operating model, Services-as-Software, to rewire discovery-to-commercial and drive measurable impact. Winning suppliers become growth partners, not just capacity providers. The next wave is precision medicine, real-world evidence, global resilient supply chains, and continuous patient engagement; vendors that bring IP/platforms and ecosystem innovation move from Horizon 2 toward Horizon 3.Listen to this conversation and review our perspective at https://www.hfsresearch.com/research/life-sciences-suppliers-black-hole/Read the HFS Horizons Report on Life Sciences Service Providers, 2025: https://www.hfsresearch.com/research/hfs-horizons-life-sciences-service-providers-2025/

As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin (University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK) about his Viewpoint editorial on a shared vision from the Global Initiative for Chronic Obstructive Lung Disease and the Global Initiative for Asthma of how to address the global challenges of COPD and asthma, published in this issue of the ERJ (https://doi.org/10.1183/13993003.02244-2025). Cite this podcast as: ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma. Eur Respir J 2026; 67: 26E6702 [https://doi.org/10.1183/13993003.E6702-2026].

“Let's inspect what we expect.” What a powerful statement. If we expect cost transparency, let's inspect what those costs have been to date. If we expect freedom of choice, let's evaluate how that has worked for employees up to this point. And let's expect an “and” approach instead of an “or” approach. As I say often these days, the devil is in the details, so it only makes sense that we put some energy and effort into inspecting what those details are and have been so we can expect what they will be in the future. That's exactly the goal and role of today's guest.  Jeff Bak is the President of Imagine360, whose mission is to reduce health plan costs for  employers, employees and their families. He has three decades of experience in managing and growing healthcare services companies. Prior to Imagine360, Jeff served as the global practice leader of the Health, Life Sciences & Business Process Outsourcing (BPO) division for Wipro Limited, and was the president and CEO of HealthPlan Holdings (HPH)—a leading healthcare solutions business.

We are excited to begin In the Public Interest's sixth season with the introduction of our new cohost Jekkie Kim. Jekkie is a corporate partner in WilmerHale's Palo Alto office who focuses on life sciences technology and transactions and works closely with founders and emerging companies to support every stage of their commercial development. In conversation with her co-host Felicia Ellsworth, Jekkie shares insights into the life sciences industry, drawing on her varied career and experience both as a practicing attorney and education as a doctor. She discusses how she leverages her medical background in her current practice, allowing her to effectively serve clients and move quickly to match the fast-moving innovations coming out of Silicon Valley. She and Felicia also share advice for law students and early-career attorneys, speaking to the importance of mentorship and how to explore potential areas of focus.

For over a thousand years, humans have been harnessing wind energy. It may have begun with small, grain‑grinding windmills in ancient Persia, but today you might spot Hoover‑Dam‑sized offshore turbines as you drive along the east coast. How did we get here? In this episode of Tiny Matters, we explore the first electric wind turbines built in the late 1800s, how government policies in the 1970s and '80s shaped the modern wind industry, and why giant offshore wind farms are suddenly in the news. We also clear up misinformation stemming from a Hollywood blockbuster as well as what we know about the impact of wind farms on whales, birds and bats.In this episode, we explore the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. We follow the development of experimental design across centuries to modern day randomized controlled trials and the debates about their limitations, trying to answer the question, “How do we know whether a treatment truly works?”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

The unprecedented rapid pace of AI and tech innovation has transformed healthcare and life science organizations. With many new answers however come lots of new questions about how to ensure continuous reinforcement of deep, hands-on knowledge of the science and detailed steps behind the art of diagnosis or steps in an experiment, and to enable the best talent in healthcare truly express itself despite the real-world struggles to find the resources they truly need and fill the job positions where their innovation can flourish.At the 2025 Medical Innovation Olympics, Tim Mikhelashvili (CEO, Amedea Pharma, Host #MIO2025) brought together an expert panel of executives in Human Resources, Life Sciences, Marketing, Founders and Investors (Kim Mack, Founder & Principal, HR Reinforced; Christina Smith, Founder, Neo HR Consulting Group; Christopher Piedmonte, Managing Director, NeoTerra Capital, and Bart Zoni, SVP Innovation & Product, Woven Health Collective) addressed a sensitive question on top of millions of people's minds in healthcare - in an AI-powered talent market, how do we hire, reward, and retain teams where deep scientific judgment and technical execution must win together—every single day? This session focused on the underlying human factors behind both layering and rewarding the best talent across science and tech in healthcare. Speakers shared practical solutions to build a strong culture that rewards both as leaders, hire, interview, onboard teams, as well as distinguish talent through innovative methods such as video submissions of candidates' CV's or work samples. 0:00 Episode Highlight 1 - Move from "No But to Yes If" in Medicine0:49 Episode Highlight 2 - Fusion of Science & Tech1:34 Opening Remarks - Lots of Talent - Few Ways to Express It3:07 Expert Panelist Introductions5:41 How do you reward Science versus Tech in Life Sciences?10:11 Hiring True Talent in the Age of AI crafted Resumes16:38 Onboarding & Retaining Best Talent 17:05 What the Tech Industry should learn from Science?19:24 What Life Science should learn from Tech20:17 Driving Quality Science despite more Informal Training21:05 Building Cross-Functional Pods across Science & Tech26:28 Q&A: How do you balance and upskill Medical Talent?27:57 Q&A: How do you work around AI to hire best talent?30:50 Q&A: Value of Video Submissions of CVs/Resumes31:42 Q&A: Work Sample or Task Completions in Interviews32:27 Final Thoughts - Optimism about Rewarding Best Talent

Send a textMike Romance has spent nearly two decades operating at the intersection of manufacturing engineering, automation, validation, and operations leadership within the life-sciences ecosystem. His career spans startups and established organizations alike, with hands-on experience taking products from early development through GMP-ready, high-volume production. Across roles in process development, automation, quality systems, and manufacturing strategy, Mike has built a reputation for combining technical rigor with pragmatic execution.Most recently at Quantum-Si, Mike played a central role in scaling operations to support the commercialization of the Platinum protein sequencing platform while laying the groundwork for next-generation technologies like the Proteus platform. Working within a lean and highly agile leadership team, he helped establish scalable manufacturing foundations spanning CM-managed instrument supply, internal reagent kit production, and advanced silicon-based consumables—while navigating the realities of fast-moving product roadmaps and constrained resources.Earlier in his career, Mike held engineering and leadership roles at organizations including Illumina, Dexcom, GenMark Diagnostics, Truvian, and Encodia. Along the way, he's led pilot-line development, automation strategy, equipment qualification, validation programs, and process controls—often in environments where the path forward wasn't clearly defined.What sets Mike apart is not just his command of acronyms—GAMP, CQV, QbD, DFSS, FMEA—but his philosophy that systems only work when people do. He actively practices emotionally intelligent leadership, prioritizing trust, clarity, and psychological safety while still holding teams to high technical and operational standards. As Mike explores his next chapter, this conversation focuses on the lessons he's learned building resilient manufacturing systems—and the kind of organizations where he believes he can make the biggest impact next.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mikeromance/Aaron Moncur, host The Wave is  a place for engineers to actively learn, share ideas, and engage with people doing similar work. Learn more at thewave.engineer Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us Watch the show on YouTube: www.youtube.com/@TeamPipelineus

We're doubling down on our YouTube content, so if you want to watch this video instead of listening to it, you can watch it on our channel here: https://www.youtube.com/@SuccessionBioAbout SuccessionSuccession helps founders and sales teams close more deals with biotech and pharma. We partner with our clients to run modern lead generation campaigns, up-skill their team through personalized sales training, and build AI workflows using cutting-edge tools and technology.Ready to take your go-to-market to the next level?

In this episode of Tiny Show and Tell Us, we explore a listener's tip about a new source of tire rubber — the Russian dandelion — and the science behind what makes it such an incredible and sustainable source of natural latex rubber. Then we answer a listener's question about a vaccine for fentanyl that will stop the drug from reaching the brain, preventing overdose.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Christine Moundas, Health Care and Data Partner at Ropes & Gray LLP and Co-Head of the firm's Digital Health Initiative, discusses the new landscape of state consumer privacy laws and how life sciences and medical device companies can comply with these new requirements. Sponsored by Ropes & Gray.Watch this episode: https://www.youtube.com/watch?v=wGUy4Bs72t4Learn more about Ropes & Gray: https://www.ropesgray.com/enEssential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Healthcare marketers are having to navigate massive shifts across the industry, including shrinking ROI timelines and increasingly complex buyer committees. In this episode, I'm joined by my two colleagues and fellow Health Launchpad principals, Mark Erwich and Matthew Piette, for a conversation about what it means to be a marketing leader in healthcare right now. We explore how the industry is moving from the traditional triple aim toward what we call the quintuple squeeze, where providers face intense pressure from regulatory changes, margin constraints, and severe staffing shortages.We provide a deep dive into how both health tech and biotech firms can adapt their strategies to remain defensible in front of CFOs. We also share our perspectives on the practical use of AI as an efficiency tool and why focusing on risk reduction may be more important than selling growth in the coming year.Key Topics Covered"(00:00:00) Introduction""(00:09:00) Big Drivers in Healthcare Technology""(00:13:00) The Quintuple Squeeze""(00:15:00) Challenges in Biotech and Life Sciences""(00:16:00) Pressure on Marketing Leaders""(00:17:00) Shortened Planning Horizons""(00:19:00) Biotech Marketing Constraints""(00:21:00) AI: Friend or Foe?""(00:26:00) Impact on Marketing Budgets""(00:30:00) Justifying Your Marketing Budget""(00:34:00) Stop Doing This to Survive""(00:37:00) Five Key Takeaways"If you are interested in discussing this or any other topic, let's have a chat.  Reach out to me directly to schedule a no-obligation discussion. This isn't a sales call, but rather an opportunity to talk through your questions and challenges.Follow me on LinkedIn.Subscribe to The Healthtech Marketing Show on Spotify or watch us on YouTube for more insights into marketing, AI, ABM, buyer journeys, and beyond!Thank you to our presenting sponsor, HealthcareNOW, 24/7 expert shows, interviews, and podcasts, powering healthcare leaders with innovation, policy, and strategy insights.

Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.

In this special ProveIt edition of Manufacturing Hub, Vlad Romanoff and Dave Griffith sit down with Amy Williams from Skellig Automation to unpack Enterprise C, a life sciences virtual factory built to look and feel like the reality inside many regulated facilities today. If you work around batch processes, compliance, historian projects, electronic batch records, or industrial data architecture, this conversation is a practical walkthrough of what it actually takes to turn raw signals into a story you can defend, improve, and scale.Amy has spent years working exclusively in life sciences manufacturing, starting deep in DeltaV automation for batch pharma and moving into digital transformation projects that focus on open architectures, modern data pipelines, and real operational outcomes. In this episode, she explains what Enterprise C is simulating, why it was designed as an Industry 3.0 style biotech startup, and what kind of data and documentation a vendor would have to wrestle with in the real world. The factory is producing a fictional enzyme using a fed batch fermentation process, and the UNS publishes realistic one second resolution batch data across four pieces of single use equipment including a mixer, a bioreactor, a chromatography skid, and a TFF skid.One of the most valuable parts of this episode is the reminder that data sitting in an MQTT broker is not inherently valuable. The value comes when the data is contextualized enough that different teams can use it without tribal knowledge, and when the resulting traceability helps you answer the questions that matter in life sciences. What happened during the batch, what changed compared to previous runs, what went out of spec, what documentation proves compliance, and what you should do next time to avoid losing a batch that can cost millions. Amy also explains why Enterprise C intentionally includes uncontextualized tags and paper files, because that is exactly where many facilities still are. The hard part is not connecting a sensor, the hard part is governance, agreement, and building a model that humans actually follow.You will also hear the crew dig into Smart Manufacturing Profiles and why standardizing information models is one of the clearest paths toward true interoperability. If you are tired of every site, every integrator, and every project reinventing the same pump, valve, and equipment model from scratch, this is the kind of conversation that helps frame why that problem keeps repeating and what might finally reduce it. The ProveIt format forces the questions that most conferences avoid, including what problem was solved, how it was done, how long it took, and what it cost. That is exactly why this conference has become a magnet for practitioners who care about the difference between a demo and a deployable solution.About the hostsVlad Romanoff is an industrial automation and manufacturing systems expert and the founder of Joltek. He has over a decade of experience modernizing control systems, data infrastructure, and plant operations across regulated and high throughput manufacturing environments.Dave Griffith is the cohost of Manufacturing Hub and a long time practitioner in industrial automation and manufacturing technology, focused on practical deployment and what actually works on the plant floor.About the guestAmy Williams works with Skellig Automation and has spent years in life sciences manufacturing, from DeltaV batch automation to digital transformation initiatives that focus on open architectures, data contextualization, and scalable modernization strategies.Timestamps 00:00 ProveIt edition intro and why this month is technology modernization 01:40 Who is Amy Williams and why Enterprise C matters this year 02:10 Amy's background in life sciences, DeltaV, and digital transformation 03:30 Unified Namespace explained in plain language for life sciences 05:10 What Enterprise C publishes and what you will see in the MQTT broker 07:10 Why UNS in life sciences is about use cases, not buzzwords 10:10 Smart Manufacturing Profiles and reducing data model reinvention 11:10 What outcomes to expect including compliance and golden batch analysis 12:10 Enterprise C process overview from mixer to bioreactor to downstream 14:10 Bioreactor instrumentation and what operators still do manually 19:40 Why Enterprise C data is intentionally not contextualized 22:10 The real work of mapping signals to compliance stories and governance 25:10 What SM Profiles enable and why schema matters before data arrives 31:30 Why cost and time questions change everything at ProveIt 36:10 Cell counter files, batch records, and paper driven reality in many sites 45:10 What life sciences attendees should ask during Q and A 58:30 Vendors the team is excited to see and why non traditional players matter 01:02:20 Where to find Skellig at the conference and what they are bringingReferences and links mentioned Skellig Automation https://www.skellig.com/ProveIt Conference https://www.proveitconference.com/CESMII Smart Manufacturing Profiles and Marketplace https://www.cesmii.org/technology/sm-profiles/ https://marketplace.cesmii.net/Joltek resources related to this episode Mastering Unified Namespace https://www.joltek.com/blog/mastering-unified-namespace-uns-a-guide-to-data-driven-manufacturing-transformation Ultimate Guide to MQTT in Manufacturing https://www.joltek.com/blog/ultimate-guide-mqtt-manufacturingSubscribe and follow Manufacturing Hub for more conversations on technology modernization, UNS architecture, MQTT, industrial data systems, and how real factories actually evolve when the goal is uptime, compliance, and measurable outcomes.

Talent mobility, specialized roles, scarce market data and other competitive pressures create unusually complex pay transparency challenges for life sciences companies. Jackson Lewis' Life Sciences Group Co-leader Peggy Strange joins podcast host Laura Mitchell to discuss how moving from pushback to preparation can address benchmarking gaps, confidentiality concerns and exception requests to protect IP and trade secrets while promoting pay transparency and pay equity compliance. 

******Support the channel******Patreon: https://www.patreon.com/thedissenterPayPal: paypal.me/thedissenterPayPal Subscription 1 Dollar: https://tinyurl.com/yb3acuuyPayPal Subscription 3 Dollars: https://tinyurl.com/ybn6bg9lPayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpzPayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9mPayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao ******Follow me on******Website: https://www.thedissenter.net/The Dissenter Goodreads list: https://shorturl.at/7BMoBFacebook: https://www.facebook.com/thedissenteryt/Twitter: https://x.com/TheDissenterYT This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/ Dr. Coleen Murphy is James A. Elkins Jr. Professor in the Life Sciences, and Professor of Molecular Biology and Director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She is the author of How We Age: The Science of Longevity. In this episode, we focus on How We Age. We discuss the science of aging, what we can learn from it, why we age, and what we can learn from animal models and centenarians. We also talk about longevity pathways, and transgenerational effects. We discuss whether intermittent fasting works. We talk about the role of DNA repair and cell replacement. We discuss whether the gut microbiome plays a role in aging. Finally, we talk about the current state of longevity biotech, and how to approach new developments.--A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, JERRY MULLER, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, ADAM HUNT, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, PAULO TOLENTINO, JOÃO BARBOSA, JULIAN PRICE, HEDIN BRØNNER, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, MICHAEL BAILEY, DAN SPERBER, ROBERT GRESSIS, JEFF MCMAHAN, JAKE ZUEHL, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, VALENTIN STEINMANN, ALEXANDER HUBBARD, BR, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, 航 豊川, TONY BARRETT, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, TED FARRIS, HUGO B., JAMES, JORDAN MANSFIELD, CHARLOTTE ALLEN, PETER STOYKO, DAVID TONNER, LEE BECK, PATRICK DALTON-HOLMES, NICK KRASNEY, RACHEL ZAK, DENNIS XAVIER, CHINMAYA BHAT, AND RHYS!A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, BENEDIKT MUELLER, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, NICK GOLDEN, CHRISTINE GLASS, IGOR NIKIFOROVSKI, AND PER KRAULIS!AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER,SERGIU CODREANU, AND GREGORY HASTINGS!

In this episode of The Steward Chair, Maria Thacker Goethe, President and CEO of Georgia Life Sciences, shares her journey of transitioning from a dedicated "number two" to leading a massive ecosystem through a global pandemic. We explore how a commitment to mission and the guidance of mentors drives meaningful, long-term success even when the original plan is upended. We discuss the critical role of a connector in the life sciences sector, the importance of "work-life harmony" over balance, and why true stewardship means preparing the next generation to lead. This conversation provides actionable takeaways for leaders committed to stewardship, integrity, and impact. Key Takeaways Purpose Over Tactics: In times of crisis, your "North Star" must be your organizational purpose, allowing your tactics to remain nimble and adaptive. The Responsibility of Mentorship: Leadership is a societal responsibility; investing time in the next generation is essential because no leader is "here forever". Embracing "Ready Enough": You don’t have to feel fully ready to step into a leadership seat; surrounding yourself with a community that believes in you is the key to moving forward through fear. Resources Mentioned Visit https://www.galifesciences.org/ Follow Maria on LinkedIn at https://www.linkedin.com/in/mariathacker/ Join the Georgia Life Sciences mailing list at: https://www.galifesciences.org/join-the-mailing-list Join the ConversationThe Steward Chair is about equipping and inspiring business leaders to build organizations that stand the test of time. If this episode resonated with you, share your biggest takeaway and tag us on LinkedIn @ChatWithLeaders. Elevate your podcast, company meeting, or industry event strategies to better engage stakeholders and drive meaningful growth! Visit ChatWithLeaders.com to learn more about how we can help.See omnystudio.com/listener for privacy information.

In 1599, a family in a small French town claimed that their daughter was possessed by a demon called Beelzebub and, despite daily exorcisms, the demon possessing this woman was staying put. So France's Henri IV set up a royal commission that would try something a little different. The woman would still receive exorcisms, complete with the normal exorcism accoutrements, but with a catch. The priest wouldn't actually be Catholic, the water in the vessel would be ordinary water, and the Latin used wouldn't be religious — it would be from Virgil's famous poem Aeneid. That's because this wasn't actually an exorcism. It was an experiment built on a deceptively simple tool that scientists and doctors still use today to study new medical treatments: a placebo.In this episode, we explore the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. We follow the development of experimental design across centuries to modern day randomized controlled trials and the debates about their limitations, trying to answer the question, “How do we know whether a treatment truly works?”Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode Justin invites first time guest, Kevin Crosby, Managing Director, Healthcare and Life Sciences at TestMu AI. With over thirty years of experience in the provider, payer and Life Sciences spaces, Kevin focuses on helping organizations bring software to market with confidence by leveraging AI to automate software engineering. Justin and Kevin share insights on AI leadership in healthcare today. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Foresters know degraded forests all too well. You're out on a woods-walk with an enthusiastic landowner, but your eyes go straight to the poor growing stock, invasive plants, and eroded forest soils – the fingerprints of past degradation. Regardless, you set about the complex task of developing a prescription that will nudge this forest towards a brighter future. Foresters don't always think of themselves as restorationists, but in many ways, the tools of silviculture are the tools of restoration. In this episode of SilviCast, we dive into the science and practice of forest restoration with John Stanturf, visiting professor at the Estonian University of Life Sciences and Senior Forest Restoration Specialist with InNovaSilva. With more than 30 years of experience researching forest restoration in both temperate and tropical forests around the world, John brings a global perspective to the question of what it means to restore a forest. Send us a text

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.